The University of Western Australia (UWA) is a globally recognised research-intensive institution, ranked among the top 100 universities worldwide. The University’s highly acclaimed researchers are dedicated to creating innovative solutions to address critical global challenges and create impact.

Our research is supported by extensive national competitive funding, long-term industry partnerships and a world-class infrastructure portfolio.

Health Research Excellence: UWA has a strong track record in health research translation, with 19 health and medical companies spun out from intellectual property, including five ASX-listed companies. Our research has led to the development of several FDA-approved drugs, innovative diagnostic tools, therapeutic interventions, and treatment strategies.

Leadership in Agricultural and Biological Sciences: UWA is ranked 1st in Australia and 9th globally in Agricultural Sciences (ARWU 2024). Dedicated field stations for testing and de-risking innovations include the 1600-hectare UWA Ridgefield farm, UWA Shenton Park Field Station, Australia’s largest recirculating aquaculture facility, and the Indian Ocean Marine Research Centre.

Ready to innovate? UWA offers access to leading researchers, talented students, advanced equipment and cutting-edge technologies. We aim to understand your business needs and shape mutually beneficial partnerships to position you at the forefront of your industry. Explore opportunities and contact our dedicated industry engagement team: uwa.edu.au/industry.

Life Sciences WA is a dynamic coalition formed in 2021, uniting key stakeholders from government, academia, research institutions, industry bodies, and corporate entities. Our mission as a peak body is to promote WA’s innovations and competitive edge on a global scale, while providing our members with invaluable networking opportunities, market insights, and resources to drive business growth and commercialisation in our state. By fostering collaboration and attracting top talent and investment, Life Sciences WA plays a pivotal role in shaping the future of the industry and influencing public policy to benefit the WA life sciences community.

The Aquaculture Council of Western Australia Inc. (ACWA) is the incorporated peak body for the Western Australian aquaculture industry. Established in 1981, ACWA is a member driven organisation working to provide strategic leadership for the sustainable development of the aquaculture industry within Western Australia, including aiding in the implementation of the Aquaculture Development Plan, and providing effective representation of aquaculture industry interests.
ACWA’s membership includes growers of a range of species including (but not limited to) abalone, bivalve shellfish, coral and live rock, marine and freshwater finfish, marron, prawns, yabbies, and seaweed and marine algae. Our interests spans from the Kimberley to Esperance and includes both marine and land-based aquaculture operators.

The Department of Energy and Economic Diversification is staffed by technical experts in energy, economics, law, resources, governance, policy, environment, heritage, project management, investment attraction and many other fields that contribute to developing economic supports for the future of the Western Australian economy.

For more than 30 years, AusIndustry has supported Australian businesses by fostering strong partnerships and networks. Working closely with businesses and communities, AusIndustry connects small and medium-sized enterprises with government support to help them grow.

This support is delivered through a nationwide network of Regional Managers who are embedded in local governments, communities, industries, and businesses. They provide impartial, tailored guidance, helping businesses identify relevant local, state, and Australian Government programs and access valuable networks.

Regional Managers support businesses across Australia—including regional, rural, and remote areas—to expand operations, commercialise ideas, and enter new markets. They also share real-time regional intelligence with government agencies, helping inform responsive policies and programs.

For 50 years, orthopaedic surgery has relied on mechanical bone-cutting tools that were the best technology available for their time. While advances in imaging, navigation and robotics have greatly improved planning and guidance, the underlying cutting method has remained largely unchanged. This has naturally placed boundaries around surgical accuracy, implant design and the ability to consistently preserve native bone and soft tissue. As demand for joint replacement grows, patient outcomes have begun to plateau and hospitals face increasing pressure on theatre capacity and waitlists. ArthroLase introduces a step change in joint replacement through HAiLO™, a robotic laser system that digitally sculpts bone with sub-millimetre precision. This transition – from mechanical cutting to intelligent digital shaping – opens the door to a new era of Faster, Better and Smarter surgery. Faster, by reducing operative time through high-speed laser shaping and streamlined digital workflows. Better, by preserving bone and soft tissue, improving implant fit and supporting more natural movement and recovery. Smarter, by lowering consumables, reducing variability and enabling advanced, bone-preserving implant designs. By expanding what is technically possible in bone preparation, ArthroLase builds on decades of orthopaedic progress and helps shape the next generation of surgical care.

Curtin University is a leader in innovation for life sciences, driving impactful research and commercialisation in healthcare, biotechnology, and medical advancements. At the heart of this innovation is the Curtin Medical Research Institute (Curtin-MRI), a multidisciplinary hub dedicated to tackling major health challenges. Curtin-MRI researchers focus on age-related diseases, chronic conditions, and precision medicine, working collaboratively with industry and government partners to translate cutting-edge discoveries into real-world applications. From developing new treatments for neurodegenerative diseases to advancing cancer diagnostics, Curtin-MRI’s work is shaping the future of healthcare.

Curtin’s Research Office and Commercialisation team play a crucial role in transforming research breakthroughs into market-ready solutions. By fostering partnerships with industry leaders and entrepreneurs, the team ensures that life-changing discoveries reach those who need them most. Their expertise in intellectual property management, licensing, and startup development supports the transition of medical innovations from lab to patient.

With state-of-the-art facilities, industry collaborations, and a strong focus on translational research, Curtin is paving the way for groundbreaking advancements in life sciences.

Edith Cowan University’s dedication to providing industry-relevant research and award-winning facilities fosters outside the box thinking and a culture that embraces creativity to tackle challenges and seize opportunities.

ECU’s world-class research delivers meaningful real-world impact and solutions to some of our greatest global challenges. ECU works closely with local communities and industry partners to ensure we are focused on the challenges that matter.

Our research partnerships are diverse and meaningful. From aged care providers to airports; the Department of Primary Industries and Regional Development to Rio Tinto; our research delivers relevant and impactful contributions to society. Whether it’s developing nature-based solutions and innovation for sustainability, or shaping the future of healthcare with genomics and precision health, ECU researchers together with industry partners are delivering the power to drive change.

With campuses in Joondalup, Mount Lawley and Bunbury, ECU is set to launch in the heart of Perth in late 2025, when ECU City opens its doors. This Perth city centred campus will be a place where technology, industry and creativity meet to deliver impactful research, and the creative thinkers, adaptive learners and global citizens who our world so desperately needs as the leaders of tomorrow.

At Fund WA, we’re committed to powering Western Australia’s most innovative, high-growth, and scalable ventures from the early stages of commercialisation. As the state’s only 100% WA-dedicated early-stage VC fund, we invest from Seed to Series A, providing the capital, expertise, and networks needed to accelerate success.

We are industry-agnostic, backing bold entrepreneurs across diverse sectors including, but not limited to software, health & life sciences, defence, energy, education, and the creative industries.

Our focus? Investing in game-changing ventures with the potential to scale globally and shape the future of WA’s economy.

Our team comprises seasoned professionals with diverse backgrounds, bringing a wealth of knowledge and experience to our portfolio companies. We encourage founders to engage with us early – starting the conversation helps us understand your vision and journey while equipping you with key insights to navigate our investment process successfully.

Charles River Laboratories provides tailored global testing and manufacturing solutions to support clients throughout the biologic development cycle, from discovery through preclinical and clinical studies to product release. Combined with our comprehensive portfolio of products and services for microbial quality control, including Endosafe® endotoxin testing, Accugenix® microbial identification, and Celsis® microbial detection, we have the necessary tools to guide clients throughout the drug development process, leading to the release of safe and effective products, including vaccines, cell and gene therapies, and biosimilars.

The WA Life Sciences Innovation Hub (WALSIH) is a state‑wide program that supports the growth and global competitiveness of Western Australia’s life sciences sector. We connect industry, researchers, clinicians, startups, and government to drive collaboration, accelerate innovation, and strengthen the commercialisation pathway for medtech, biotech, digital health, and pharmaceutical ventures. The Hub provides strategic sector development, industry engagement, capability‑building initiatives, and support services that help position WA as a leading destination for life sciences innovation and investment.

CERI (Centre for Entrepreneurial Research and Innovation) is a social enterprise dedicated to empowering the next generation of Western Australians to think differently, innovate, and build high-knowledge, high-value ventures. We deliver world-class programs, mentoring, and a supportive community to help aspiring entrepreneurs turn ideas into scalable businesses.

Innovate Medtech is a global medtech advisory and product development company transforming innovative medical device ideas into market-ready solutions. By combining engineering and scientific expertise with intellectual property, regulatory strategy and product design, the team ensures devices are unique, patentable and commercially positioned for success.

Website: https://www.innovatemed.tech/

Epichem is an Australian contract research organisation (CRO) delivering synthetic and medicinal chemistry services to pharmaceutical, biotechnology, industrial and academic partners worldwide. From hit-to-lead and lead optimisation through to custom synthesis, scale-up and analytical characterisation, we help advance complex molecules from concept toward application. Our Perth-based team provides high-quality, IP-secure research on a fee-for-service basis, supporting small-molecule drug discovery as well as specialty chemicals, advanced materials and research reagents. Epichem’s fully onshore R&D capability enables organisations to accelerate programs while retaining IP and meeting Australian sovereign capability and research-spend objectives. With more than 20 years’ experience and a strong track record with global clients, Epichem is a trusted chemistry partner across discovery, development and manufacturing support.

Website: https://www.epichem.com/